Emmaus Life Sciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Emmaus Life Sciences, Inc. - overview
Established
2000
Location
Torrance, CA, US
Primary Industry
Biotechnology
About
Emmaus Life Sciences, Inc. is a biotechnology firm dedicated to developing and commercializing treatments for rare diseases, particularly focusing on sickle cell disease and diverticulosis. Founded in 2000 and based in Torrance, California, Emmaus Life Sciences, Inc. specializes in therapies for rare and orphan diseases.
The company has raised a total of USD 20. 00 mn, with the latest funding round being VENTURE DEBT amounting to USD 30. 00 mn from GPB Capital on January 21, 2018. Emmaus has completed six total deals in its history, focusing on innovative healthcare solutions.
Emmaus Medical, Inc. primarily focuses on the discovery, development, and commercialization of innovative treatments targeting rare diseases, with a significant emphasis on sickle cell disease (SCD) and diverticulosis. The flagship product, Endari® (L-glutamine oral powder), is designed to reduce complications associated with SCD and is marketed in the United States, Puerto Rico, Oman, Bahrain, and Kuwait. The company implements a robust support program to facilitate patient access to its therapies.
In 2023, Emmaus Medical, Inc. reported a revenue of USD 29. 60 mn, with an EBITDA of USD 6. 14 mn.
Revenue is primarily generated through the sale of Endari®, which is distributed to healthcare facilities and specialty pharmacies, leveraging both B2B and direct-to-consumer models. Emmaus Life Sciences plans to continue expanding its product offerings and market presence. The company aims to enhance its pipeline of treatments targeting rare diseases and is exploring new geographic markets. Recent funding from the VENTURE DEBT round will be utilized to support product development and market expansion efforts, aiming for strategic growth in regions that have been previously underserved.
Specific timelines for product launches and geographical expansions will be communicated as they develop.
Current Investors
Agility Capital, Hanil Vacuum Co., Ltd., KPM Tech Co., Ltd.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.emmausmedical.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Emmaus Life Sciences, Inc. - timeline of key events
Emmaus Life Sciences, Inc. - financials
| Fiscal Year Ended | Sep 30, 2013 | Sep 30, 2014 | Sep 30, 2015 | Sep 30, 2016 | Sep 30, 2017 | Sep 30, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 130,900 | 135,100 | 100,100 | 85,100 | 128,500 | 1,315,500 | 22,752,000 | 23,167,000 | - | - | - |
| % Revenue Growth (YoY) | - | 3.2% | (25.9%) | (15.0%) | 51.0% | 923.7% | - | - | - | - | - |
| EBITDA (USD) | (3,525,300) | (3,801,500) | (2,496,100) | (3,759,600) | (7,054,900) | (10,127,000) | 19,342,000 | 4,055,000 | - | - | - |
| Operating Income (USD) | (4,200,600) | (3,816,800) | (2,656,400) | (3,766,800) | (7,103,600) | (10,244,900) | (4,512,000) | (32,000) | - | - | - |
| Operating Margin | (3209.0%) | (2825.2%) | (2653.7%) | (4426.3%) | (5528.1%) | (778.8%) | (19.8%) | (0.1%) | - | - | - |
| % EBITDA Margin | (2693.1%) | (2813.8%) | (2493.6%) | (4417.9%) | (5490.2%) | (769.8%) | 85.0% | 17.5% | - | - | - |
| NET Income (USD) | (10,907,400) | (2,662,800) | (3,379,400) | (5,940,900) | (7,112,800) | (10,333,100) | (54,842,000) | 1,100,000 | - | - | - |
| % Net Margin | (8332.6%) | (1971.0%) | (3376.0%) | (6981.1%) | (5535.3%) | (785.5%) | (241.0%) | 4.7% | - | - | - |
Emmaus Life Sciences, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.